clinical trial semaglutide Overview of the global PIONEER program for oral Oral semaglutide versus subcutaneous liraglutide

Semaglutide was originally developed to treat type 2 diabetes, but in recent years, it has become a breakthrough in weight management after scientists discovered its ability to control appetite, regulate blood sugar levels, and promote sustainable weight loss

This mechanism is the focus of most current research interest, particularly in studies on stubborn visceral fat and metabolic regulation

Nat Med 30:20582066 Cheng Y, Zheng H, Yin H, Yin D, Wang H, Wang Y, Tang Q, Gu S (2024) Changes in metabolic overweight phenotypes over time and risk of nephrolithiasis: a cohort study

Support for these services was funded by Novo Nordisk